CD274 and familial pancreatic carcinoma: However, since BET inhibitors decrease PD-L1, and thereby decrease the ‘target’ for the PD-1/PD-L1 checkpoint inhibitors, in future studies we will evaluate the relative efficacy of combining BET inhibitors with anti-PD-1/PD-L1 antibodies or with other immune checkpoint inhibitors, such as anti-CTLA4 antibodies31, in transgenic mouse models of pancreatic cancer.